Oscotec (A039200) Stock Overview
Operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A039200 from our risk checks.
A039200 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Oscotec Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩42,100.00 |
| 52 Week High | ₩43,600.00 |
| 52 Week Low | ₩21,600.00 |
| Beta | 1.61 |
| 1 Month Change | 33.44% |
| 3 Month Change | 49.82% |
| 1 Year Change | 24.19% |
| 3 Year Change | 121.58% |
| 5 Year Change | 2.68% |
| Change since IPO | 463.21% |
Recent News & Updates
Despite Lacking Profits Oscotec (KOSDAQ:039200) Seems To Be On Top Of Its Debt
Aug 13
Oscotec Inc. (KOSDAQ:039200) Not Flying Under The Radar
Jul 03Oscotec Inc. (KOSDAQ:039200) Looks Just Right With A 26% Price Jump
Mar 26Rock star Growth Puts Oscotec (KOSDAQ:039200) In A Position To Use Debt
Feb 16With A 38% Price Drop For Oscotec Inc. (KOSDAQ:039200) You'll Still Get What You Pay For
Nov 20Recent updates
Despite Lacking Profits Oscotec (KOSDAQ:039200) Seems To Be On Top Of Its Debt
Aug 13Oscotec Inc. (KOSDAQ:039200) Not Flying Under The Radar
Jul 03Oscotec Inc. (KOSDAQ:039200) Looks Just Right With A 26% Price Jump
Mar 26Rock star Growth Puts Oscotec (KOSDAQ:039200) In A Position To Use Debt
Feb 16With A 38% Price Drop For Oscotec Inc. (KOSDAQ:039200) You'll Still Get What You Pay For
Nov 20Oscotec (KOSDAQ:039200) Has Debt But No Earnings; Should You Worry?
Aug 07Is Oscotec (KOSDAQ:039200) Using Debt In A Risky Way?
Apr 26Is Oscotec Inc.'s (KOSDAQ:039200) Shareholder Ownership Skewed Towards Insiders?
Feb 23If You Had Bought Oscotec (KOSDAQ:039200) Shares Five Years Ago You'd Have Earned 353% Returns
Jan 19
Is Oscotec (KOSDAQ:039200) Using Debt Sensibly?
Dec 15Shareholder Returns
| A039200 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 14.6% | 2.7% | 0.3% |
| 1Y | 24.2% | 4.1% | 22.1% |
Return vs Industry: A039200 exceeded the KR Pharmaceuticals industry which returned 4.1% over the past year.
Return vs Market: A039200 exceeded the KR Market which returned 22.1% over the past year.
Price Volatility
| A039200 volatility | |
|---|---|
| A039200 Average Weekly Movement | 6.3% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in KR Market | 10.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A039200 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A039200's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 53 | James Kim | oscotec.com |
Oscotec Inc. operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses. It develops SKI-O-703, a SYK inhibitor that is in Phase 2 clinical trials to treat rheumatoid arthritis and idiopathic thrombocytopenic purpura; SKI-G-801, a selective FLT3/AXL inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia, as well as other solid tumors; and lazertinib, a 3rd generation EGFR inhibitor that is in Phase 3 clinical trials to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in Phase 1a/1b clinical trials for the treatment of Alzheimer’s disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide.
Oscotec Inc. Fundamentals Summary
| A039200 fundamental statistics | |
|---|---|
| Market cap | ₩1.61t |
| Earnings (TTM) | ₩4.25b |
| Revenue (TTM) | ₩43.34b |
Is A039200 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A039200 income statement (TTM) | |
|---|---|
| Revenue | ₩43.34b |
| Cost of Revenue | ₩2.46b |
| Gross Profit | ₩40.88b |
| Other Expenses | ₩36.63b |
| Earnings | ₩4.25b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 111.20 |
| Gross Margin | 94.32% |
| Net Profit Margin | 9.81% |
| Debt/Equity Ratio | 11.4% |
How did A039200 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/05 23:03 |
| End of Day Share Price | 2025/09/05 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oscotec Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Heeyoung Lee | Daishin Securities Co. Ltd. |
| Haesoon Kwon | Eugene Investment & Securities Co Ltd. |
| Sangsoo Kim | Goldman Sachs |